Pernicious Anemia: Type II Hypersensitivity Reaction
Pernicious anemia is a non-cytotoxic type II hypersensitivity reaction. Autoantibodies target intrinsic factor (IF) or parietal cell antigens (H+/K+ ATPase), leading to vitamin B12 malabsorption.
Mechanism
- Anti-intrinsic factor antibodies (type 1: block B12 binding; type 2: block IF-B12 complex binding to ileal receptor).
- Anti-parietal cell antibodies (85–90% of patients) – destroy parietal cells → achlorhydria, IF deficiency.
- Complement activation and cell-mediated immunity contribute to gastric atrophy.
Distinction from Cytotoxic Type II
Classic cytotoxic type II (e.g., autoimmune hemolytic anemia, ITP) involves antibody-mediated cell lysis via complement or ADCC. Pernicious anemia's primary pathology is functional blockade and atrophy rather than direct lysis of mature cells—hence "non-cytotoxic."
Clinical Features
- Macrocytic anemia, neuropathy (subacute combined degeneration), glossitis.
- Diagnosis: low B12, elevated methylmalonic acid/homocysteine, positive antibodies.
- Treatment: lifelong parenteral (IM) or high-dose oral B12.
Blood Disorders - Related Articles
- Accidental Intravenous Injection: Emergency Response and Serious Risks
- Hyperbilirubinemia and Seizures: Understanding the Connection
- Understanding Pulse Oximetry: What It Measures & Why
- Understanding MPV Blood Test Results: A Comprehensive Guide
- After Blood Donation: Why You Should Avoid Strenuous Exercise
- Causes of Vomiting Blood (Hematemesis): Symptoms and Treatments
- Phlebotomy License Requirements: State-by-State Overview
